Repligen (NASDAQ:RGEN) Price Target Raised to $180.00

Repligen (NASDAQ:RGEN) had its target price lifted by equities researchers at Canaccord Genuity Group from $145.00 to $180.00 in a report issued on Monday, Benzinga reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 2.61% from the company’s current price.

Several other equities analysts also recently weighed in on the stock. Weiss Ratings upgraded shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Zacks Research lowered shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. JPMorgan Chase & Co. increased their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Citigroup raised shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Finally, Wells Fargo & Company lifted their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.71.

Repligen Price Performance

Repligen stock opened at $175.42 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market capitalization of $9.90 billion, a price-to-earnings ratio of 240.30, a price-to-earnings-growth ratio of 3.20 and a beta of 1.08. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $198.87. The stock’s fifty day moving average is $175.86 and its two-hundred day moving average is $145.75.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts predict that Repligen will post 2.06 EPS for the current fiscal year.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the second quarter worth about $380,756,000. Wasatch Advisors LP lifted its stake in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after buying an additional 346,720 shares during the period. Congress Asset Management Co. lifted its stake in shares of Repligen by 0.9% during the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock valued at $196,249,000 after buying an additional 8,681 shares during the period. ABS Investment Management LLC acquired a new stake in Repligen during the second quarter worth approximately $191,016,000. Finally, Maverick Capital Ltd. acquired a new stake in Repligen during the first quarter worth approximately $178,946,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.